JP7134703B2 - Adrenal hypofunction inhibitor - Google Patents

Description

TECHNICAL FIELD The present invention relates to an adrenal insufficiency inhibitor containing milk protein as an active ingredient.

When the body receives stress, cortisol (corticosterone in rodents) is released from the adrenal cortex via corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH). secreted.

Cortisol and corticosterone are known to have a blood pressure-increasing effect, a blood-sugar-increasing effect, an anti-inflammatory effect, and the like, and play a role in promoting a biological response to resist stress. On the other hand, it has been reported that decreased cortisol secretion due to decreased adrenal function induces fatigue and weakness (see, for example, Non-Patent Document 1). It is believed that overuse of the adrenal glands by chronic exposure to excessive stress results in adrenal hypofunction. In fact, there is also a report that people who feel fatigue due to stress have reduced adrenal function (see, for example, Non-Patent Document 2).

Therefore, especially in modern society, it can be said that there is a demand for suppressing deterioration of adrenal function due to stress, etc., and promoting a biological response that resists stress.

Arlt W et al., Lancet, 361, 1881-1893, 2003. Oosterholt et al., Journal of Psychosomatic Research, 78, 445-451, 2015.

The present inventors have found that by allowing a subject to ingest milk protein, it is possible to suppress the deterioration of adrenal function in the subject.

Accordingly, an object of the present invention is to provide an agent for suppressing adrenal insufficiency, a method for suppressing adrenal insufficiency, and the like.

According to the present invention, the following inventions are provided.
(1) An adrenal hypofunction inhibitor containing milk protein as an active ingredient.
(2) The inhibitor of adrenal insufficiency according to (1), which is an inhibitor of adrenal hypofunction.
(3) The inhibitor of adrenal insufficiency according to (1), which is a cortisol or corticosterone hyposecretion inhibitor.
(4) The inhibitor of adrenal insufficiency according to any one of (1) to (3), which is ingested by a subject under stress.
(5) The adrenal hypofunction inhibitor according to any one of (1) to (4), which is ingested by a subject under heat stress.
(6) The adrenal hypofunction inhibitor according to any one of (1) to (5), wherein the milk protein is casein protein or whey protein.
(7) The inhibitor of adrenal insufficiency according to any one of (1) to (6), wherein the milk protein is ingested in humans so that the total protein amount is 0.2 g/kg body weight or more per day. .
(8) Any one of (1) to (6), which consists of a unit packaging form per meal, and contains 5 g or more of milk protein as a total protein amount per meal in the unit packaging form. Adrenal hypofunction inhibitor.
(9) A composition for suppressing adrenal insufficiency, containing milk protein as an active ingredient.
(10) A stress-relieving agent for reducing fatigue, containing milk protein as an active ingredient.
(11) A food for suppressing adrenal insufficiency, containing milk protein as an active ingredient. (12) A food for reducing fatigue under stress load, containing milk protein as an active ingredient.
(13) A method for suppressing adrenal insufficiency, which comprises the step of allowing a subject to ingest milk protein.
(14) A method for suppressing adrenal insufficiency, which comprises the step of allowing a subject to ingest milk protein (excluding medical practice for humans).
(15) The method for suppressing adrenal insufficiency according to (13) or (14), which comprises the step of allowing humans to ingest milk protein so that the total protein amount is 0.2 g/kg body weight or more per day.
(16) A method for reducing fatigue, which comprises the step of allowing a subject under stress to ingest milk protein.
(17) A method for reducing fatigue, which comprises the step of allowing a subject under stress to ingest milk protein (excluding medical practice on humans).
(18) The method for reducing fatigue according to (16) or (17), which comprises the step of allowing humans to ingest milk protein so that the total protein amount is 0.2 g/kg body weight or more per day.
(19) Use of milk protein for the production of an adrenal insufficiency inhibitor.
(20) Use of milk protein for producing a composition for suppressing adrenal insufficiency.
(21) Use of milk protein for the production of a fatigue-reducing agent during stress loading.
(22) Use of milk protein for suppressing adrenal insufficiency.
(23) Use of milk protein for reducing fatigue during stress loading.

ADVANTAGE OF THE INVENTION According to this invention, it is advantageous in that it can provide the agent which can suppress hypofunction of an adrenal gland. Moreover, according to the present invention, it is also advantageous in that it is possible to provide an agent capable of reducing fatigue during stress loading.

Figure 1 shows the amount of spontaneous activity during the dark period. Heat 1 to 4 represent the amount of spontaneous activity when animals were fed with a non-low protein diet and a low protein diet on days 1 to 4 of heat stress, respectively. * indicates p<0.05 when comparing groups by t-test. # represents p<0.05 when compared to Baseline by Dunnett's test and ## represents p<0.01 when compared to Baseline by Dunnett's test. FIG. 2 shows changes in corticosterone concentration in plasma. The horizontal axis represents the time (minutes) after ACTH administration, and the vertical axis represents the plasma corticosterone concentration (ng/mL). * indicates p<0.05 when comparing the non-low-protein diet group subjected to heat stress and the low-protein diet group subjected to heat stress by t-test. FIG. 3 represents the AUC (Area under the blood concentration-time curve) of corticosterone concentration in plasma. In FIG. 3, the "non-low-protein diet group" represents a group fed with a feed with a high protein content, and the "low-protein diet group" represents a group fed with a low-protein feed. * indicates p<0.05 when compared with the group given the non-low-protein diet under heat stress by t-test.

Specific description of the invention

The present invention is an adrenal hypofunction inhibitor containing milk protein as an active ingredient.

In the present invention, the “active ingredient” means an ingredient that is necessary for suppressing hypofunction of the adrenal glands or for alleviating fatigue under stress.

The milk protein contained in the agent for suppressing adrenal insufficiency of the present invention is not particularly limited as long as it is a milk-derived protein. It may be a milk protein from mammalian milk such as dolphin milk or human milk. In addition, the milk protein of the present invention includes, for example, whey protein, casein protein, whey protein hydrolyzate, casein protein hydrolyzate, peptide, or non-protein nitrogen component at a specific concentration (content). , casein protein or whey protein. This "milk protein" is a mixture of separately isolated and purified whey proteins, casein proteins, whey protein hydrolysates, casein hydrolysates, peptides, or non-protein nitrogen components at specific concentrations. may be used or already contains specified concentrations of whey protein, casein protein, whey protein hydrolysates, casein hydrolysates, peptides, or non-protein nitrogen components that have not been separately separated or purified Raw materials (materials), food and drink, and the like may be used. At this time, the "milk protein" used in the present invention does not require a separation step or a purification step for whey protein, casein protein, whey protein hydrolyzate, casein hydrolyzate, peptides, and non-protein nitrogen components, and these Whey protein, casein protein, whey protein hydrolyzate, casein hydrolyzate, or raw materials, foods and beverages that already contain peptides and non-protein nitrogen components at specific concentrations are the main products because of their low manufacturing costs. As a component, if necessary, separately purified whey protein, casein protein, whey protein hydrolyzate, casein protein hydrolyzate, or peptide and non-protein nitrogen components may be mixed to a specific concentration. can be done.

As the milk protein contained in the agent for suppressing adrenal insufficiency of the present invention, one type of milk may be used alone, or two or more types of milk may be mixed and used. For this milk protein, a highly pure component such as a chemical product (reagent, etc.) may be used, or a mixed component such as an isolated product or a purified product may be used. Here, the protein content may be calculated, for example, based on known information such as the Food Composition Table, or may be calculated by measuring by a commonly used method such as the Kjeldahl method or the Lowry method. Actually, in the case of the Kjeldahl method, the nitrogen contained in various proteins is measured, and the nitrogen-protein conversion factor (usually 6.25) is multiplied to calculate the nitrogen content.

The concentration of the milk protein contained in the adrenal insufficiency inhibitor of the present invention is not particularly limited as long as it does not interfere with the effects of the present invention. 5 to 98% by mass, more preferably 5 to 75% by mass, still more preferably 10 to 50% by mass, still more preferably 15 to 25% by mass, particularly preferably 18 to 22% by mass. be. By adjusting the concentration of milk protein contained in the agent for suppressing adrenal insufficiency of the present invention to 15 to 25% by mass, it is possible to further suppress adrenal insufficiency and reduce fatigue during stress loading. . The concentration of milk protein contained in the agent for suppressing adrenal insufficiency of the present invention can be measured, for example, by the Kjeldahl method.

Adrenal insufficiency in the agent for suppressing adrenal insufficiency of the present invention may be either a decrease in function of the adrenal cortex or the adrenal medulla, preferably a hypofunction of the adrenal cortex, more preferably cortisol or corticosteroid. This is a decrease in the secretion of In humans, the adrenal cortex secretes cortisol, and in rodents, the adrenal cortex secretes corticosterone. When the function of the adrenal glands decreases, especially when the function of the adrenal cortex decreases, the secretion of cortisol and corticosterone decreases, and the blood pressure-increasing action, blood glucose-increasing action, anti-inflammatory action, etc. are suppressed. In addition, fatigue, general malaise, depressive symptoms, aggravation of allergic symptoms, anorexia, hypoglycemia, palpitations, hyperventilation, decreased concentration, etc. are induced. Therefore, by using the inhibitor of adrenal insufficiency of the present invention (preferably, an inhibitor of adrenocortical insufficiency, more preferably an inhibitor of cortisol or corticosterone secretion reduction), these effects can be suppressed and fatigue can be improved. can do.

The agent for suppressing adrenal insufficiency of the present invention is preferably ingested by a subject under stress. A subject under stress can be any subject under stress, but a subject under chronic stress may have lower levels of cortisol or corticosterone secretion, leading to feelings of fatigue and fatigue. Since it is believed that more weakness is induced, it is more effective to use the agent for suppressing adrenal insufficiency of the present invention in such subjects. In addition, the effect of the present invention can be further exhibited by using the agent for suppressing adrenal insufficiency of the present invention in a subject under heat stress. In the present invention, the subject includes non-human animals (livestock such as horses and cows, pet animals such as dogs and cats, and ornamental animals kept in zoos and the like). Here, stress is defined as a biological reaction to a stimulus that disturbs the homeostasis of the body. radiation, etc.), chemical stressors (oxygen, drugs, etc.), biological stressors (inflammation, infection, etc.), and psychological stressors (anger, anxiety, etc.). The stress in the present invention may be stress caused by any of the stressors described above. Ingestion by the subject under stress is particularly preferred.

The intake of milk protein contained as an active ingredient in the agent for suppressing adrenal insufficiency of the present invention is not particularly limited. Body weight or more, more preferably 0.3 g/kg body weight or more, milk protein is 0.2-2.5 g/kg body weight, preferably 0.3-2. It is taken at 0 g/kg body weight, more preferably 0.3 to 1.0 g/kg body weight.
The required dosage of the active ingredient described above can be converted from the required dosage in animal experiments (for example, mouse experiments) into the required dosage for humans using the following formula based on the data of the Food Safety Commission.

According to a preferred embodiment of the present invention, the inhibitor of adrenal insufficiency of the present invention is in a unit packaging form per meal, and in the unit packaging form, the total protein amount is 5 g or more as one meal intake of milk protein, It preferably contains 7 g or more, and more preferably contains 5 to 50 g, more preferably 7 to 25 g, and particularly preferably 10 to 25 g of milk protein as a total protein amount per serving. Here, "consisting of a unit packaging form per meal" means that the intake amount per meal is predetermined. (drinks, etc.), health supplements, foods with health claims, supplements, and the like. In the case of "unit packaging form per serving", for example, in the case of liquid beverages, gel-like, paste-like or paste-like jelly, powder-like, granule-like, capsule-like or block-like solid foods, etc. , metal cans, glass bottles (bottles, etc.), plastic containers (PET bottles, etc.), packs, pouches, film containers, paper boxes, etc., in which a specific amount (dose) can be specified, or the amount of intake per meal (usage , dosage) can be specified on the packaging container or on the website. Alternatively, there is a form in which a measuring instrument such as a spoon that can measure the intake per meal is attached.

The agent for suppressing adrenal insufficiency of the present invention may contain ingredients other than milk protein, such as dietary fiber, stabilizers, lipids, carbohydrates, vitamins and minerals.

Dietary fiber is not particularly limited as long as it does not interfere with the effects of the present invention, but is edible that originally exists in foods, is obtained by physical, enzymatic or chemical treatment, or is synthesized. is mentioned. Moreover, the dietary fiber may be a high-molecular-weight water-soluble dietary fiber, a low-molecular-weight water-soluble dietary fiber, or an insoluble dietary fiber. Examples of such dietary fibers include cellulose, carboxymethylcellulose, agar, xanthan gum, psyllium seed coat, dulan gum, low-molecular-weight sodium alginate, propylene glycol alginate, polydextrose, gum arabic, indigestible dextrin, beet fiber, guar gum, and guar gum enzymatic decomposition products. , wheat germ, heat-moisture treated starch (resistant starch), resistant starch, tamarind seed gum, locust bean gum, pullulan, and polysaccharides such as inulin. Dietary fibers include oligosaccharides such as galacto-oligosaccharides, fructo-oligosaccharides, milk oligosaccharides, beet oligosaccharides, gentioligosaccharides, xylooligosaccharides and soybean oligosaccharides, and combinations of these oligosaccharides.

Stabilizers include water soluble soy polysaccharides, cellulose, carboxymethyl cellulose, alginic acid, propylene glycol alginate, starch, modified starch, carrageenan, xanthan gum, gellan gum, tamarind seed gum, tara gum and combinations thereof.

The lipid is not particularly limited as long as it can be used for food or pharmaceutical applications, and any lipid may be used. Such lipids include vegetable oils, animal oils, microbial oils, synthetic triglycerides, phospholipids, and the like. These may be used alone or in any combination.

Carbohydrates are not particularly limited as long as they do not interfere with the effects of the present invention. Examples include saccharides, modified starches (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.).

Vitamins are not particularly limited as long as they can be used for foods or medicines, and may be of one type or a mixture of multiple types.

The minerals are not particularly limited as long as they can be used for foods or medicines, and may be of one type or a mixture of multiple types.

According to another aspect of the present invention, there is provided a composition for suppressing adrenal insufficiency, containing milk protein as an active ingredient. Further, according to another aspect of the present invention, there is provided a composition for reducing fatigue under stress, containing milk protein as an active ingredient. These compositions include both food compositions and pharmaceutical compositions (drugs). As used herein, foods also include beverages. In addition, these compositions can be in the form of solids (powder, granules, capsules, blocks, etc.), liquids, gels, pastes, pastes, and the like. It may contain agents, lipids, vitamins, minerals, and the like. A pharmaceutical composition (pharmaceutical) is prepared as an oral preparation or a parenteral preparation according to a conventional method by using additives that are acceptable for formulation. When the pharmaceutical composition is an oral formulation, it may be solid formulations such as tablets, powders, fine granules, granules, capsules, pills, sustained-release formulations, or liquid formulations such as solutions, suspensions, and emulsions. can take form. From the viewpoint of ease of ingestion (administration) to patients, the pharmaceutical composition is preferably an oral preparation. Here, additives acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, colorants, flavors, buffers, antioxidants, agents, pH adjusters, and the like. The pharmaceutical composition (pharmaceutical) of the present invention can be applied to any disease that requires suppression of hypofunction of the adrenal glands or alleviation of fatigue under stress load. For example, it can be used for the treatment or prevention of diseases caused by blood pressure, blood sugar, inflammation, and metabolic disorders, and particularly for the treatment or prevention of heatstroke, summer fatigue, or indefinite complaints.

According to another aspect of the present invention, there is provided an agent for reducing fatigue under stress, containing milk protein as an active ingredient. Further, according to another aspect of the present invention, there is provided a composition for reducing fatigue under stress, containing milk protein as an active ingredient.

According to another aspect of the present invention, there is provided a method for suppressing adrenal insufficiency, which comprises the step of allowing a subject to ingest milk protein. According to a preferred embodiment of the present invention, there is provided a method for suppressing adrenal insufficiency (excluding medical practice for humans), which comprises the step of allowing a subject to ingest milk protein. Here, "medical practice on humans" means the practice of ingesting (administering) pharmaceuticals to humans, etc., requiring a prescription from a doctor or the like.

According to a preferred embodiment of the present invention, there is provided a method for suppressing adrenal insufficiency, which comprises the step of allowing a human to ingest milk protein so that the total protein amount is 0.2 g/kg body weight or more per day.

According to another aspect of the present invention, there is provided a fatigue alleviating method comprising the step of ingesting milk protein to a subject under stress. According to a preferred embodiment of the present invention, there is provided a method for reducing fatigue (excluding medical practice on humans), which comprises the step of ingesting milk protein to a subject under stress. Here, "medical practice on humans" means, as described above, the practice of ingesting (administering) pharmaceuticals to humans requiring a prescription from a doctor or the like.

According to a preferred embodiment of the present invention, there is provided a fatigue alleviating method comprising the step of allowing a human to ingest milk protein such that the total protein amount is 0.2 g/kg body weight or more per day.

According to another aspect of the present invention, there is provided a food for suppressing adrenal insufficiency, containing milk protein as an active ingredient. Moreover, according to another aspect of the present invention, there is provided a food for reducing fatigue under stress, containing milk protein as an active ingredient. Here, the food for suppressing adrenal insufficiency or the food for reducing fatigue under stress refers to food containing milk and/or dairy products. Here, the milk is, for example, milk derived from mammals such as cow's milk, sheep's milk, goat's milk, buffalo milk, sheep's milk, camel's milk, whale's milk, dolphin's milk, and human's milk. Here, the dairy product is a product obtained by processing milk, and known liquid raw materials such as skim milk, partially skim milk, desalted skim milk, desalted milk, adjusted milk, whey, concentrated milk , skimmed concentrated milk, partially skimmed concentrated milk, desalted skimmed concentrated milk, condensed milk, cream, permeate derived from dairy raw materials prepared by a known method, milk protein concentrate prepared by a known method, etc. Other raw materials such as milk powder, butter, cheese, concentrated milk, condensed milk, lactose, whey minerals, etc. can also be used.

The food and drink products of the present invention include liquid diets, health foods, functional foods, dietary supplements, foods for specified health uses, foods with function claims, foods for sick people, and the like.

The present invention will be specifically described based on the following examples, but the present invention is not limited to these examples.

Test example 1. Effect of milk protein intake on spontaneous behavior after stress load
[Method]
Six-week-old ICR male mice were purchased from Japan SLC and acclimatized for one week. AIN-76 (Research Diet Co.) was used as the feed. Mice were divided into two groups: (1) a non-low protein diet group (a group fed with a high protein content) and (2) a low protein diet group (a group fed with a low protein feed) and acclimatized for one week. After feeding, the animals were switched to each feed. The composition of the feed used is shown in Table 1 below. The non-low protein diet group received AIN-76 (Research Diet Inc.) (non-low protein diet). The low-protein diet group was given a diet (low-protein diet) in which half of the milk protein in AIN-76 was replaced with sugar (Research Diet), and compared to the non-low-protein diet group, the nutritional status was insufficient in milk protein. and After switching the feed, the animals were bred for 2 weeks using a spontaneous activity measuring device ROC-100 (Shin Factory Co., Ltd.). was measured daily. Body weight, food consumption, and water consumption were measured during the study period. Four days before two weeks had passed since the diet was switched, heat stress was applied to the mice using a temperature-controlled chamber HC-100 for small animals (Shin Factory). The loading conditions were 35±1° C. and 2 hours. In addition, the average value for 4 days before the heat stress load was calculated as the Baseline value.

[result]
Spontaneous activity in the dark period was significantly lower in the low-protein diet group on days 1 to 4 after heat stress load than in each baseline. In addition, the low-protein diet group showed significantly lower spontaneous activity during the dark period on the 1st and 4th days of the heat stress load compared to the non-low-protein diet group. These results indicated that stress loading under low-protein diet conditions slightly fatigued the mice and decreased their locomotor activity during the dark period. The results are shown in FIG.
The daily dose of protein to the mice used in the test was about 27.9 g/kg body weight on average in the non-low protein diet group and about 15.7 g/kg body weight in the low protein diet group. rice field.

Test example 2. Effect of different milk protein intakes on adrenal function after stress load
[Method]
Subjects under stress have been reported to have reduced adrenal function. Adrenal insufficiency, which is a disease in which adrenal function is decreased and cortisol secretion is significantly decreased, is characterized by fatigue, and other symptoms such as nausea and anxiety have been reported. Therefore, we used the ACTH challenge test, which is widely used to evaluate adrenal function, to evaluate whether hypoadrenal function is involved in fatigue caused by heat stress under non-low and low-protein intake conditions. . Here, the ACTH stress test is a test to examine adrenal function by administering synthetic ACTH (cortrocin) and measuring the cortisol level at a predetermined time before and after stress.

Six-week-old ICR male mice were purchased from Japan SLC and acclimatized for one week. AIN-76 (Research Diet Co.) was used as the feed. Heat stress was applied to the mice, and divided into two groups: (1) non-low protein diet group (group fed with diet with not a small amount of protein) and (2) low protein diet group (group fed with low protein diet). divided and switched to each diet. The non-low protein diet group received AIN-76 (Research Diet Inc.) (non-low protein diet). The low-protein diet group was fed with a diet in which half of the protein in AIN-76 was replaced with carbohydrate (Research Diet Co.) to create a protein-deficient nutritional state compared to the non-low-protein diet group. From 4 days before 2 weeks had passed since the diet was switched, heat stress was applied to the mice in the heat stress load group using a small animal temperature control chamber HC-100. The loading conditions were 35±1° C. and 2 hours.

The ACTH load test was carried out on the next day after the end of the 4-day heat stress load. 100 μg/kg of cortrocin (manufactured by Daiichi Sankyo Co., Ltd.) was intraperitoneally administered, and blood was collected from the tail vein 30 minutes before administration, immediately before administration, and 30, 60 and 90 minutes after administration. In the non-loaded group, administration and blood collection were performed in the same manner two weeks after the feed change. Blood was centrifuged at 12,600 xg for 5 minutes and the resulting plasma was stored at -80°C. The corticosterone concentration in tail vein blood plasma was measured by Corticosterone EIA Kit (Arbor Assays).

[result]
The plasma corticosterone concentration in the heat-stressed low-protein diet group was significantly lower at 30 and 60 minutes after ACTH administration than in the heat-stressed, non-low-protein diet group. When the AUC in the ACTH stress test was calculated, the heat stress-loaded low-protein diet group showed significantly lower values than the heat stress-loaded non-low-protein diet group. These results are shown in FIGS. 2 and 3. FIG. In addition, the non-low protein diet group subjected to heat stress showed changes in plasma corticosterone concentrations similar to those of the non-low protein diet group not subjected to heat stress. , plasma corticosterone concentration was found to recover to the level not subjected to heat stress (data not shown).

Based on the results of the locomotor activity measurement test and the ACTH challenge test, under stress load, milk protein intake, especially sufficient milk protein intake, suppresses adrenocortical hypofunction, thereby reducing locomotor activity during the dark period. It is thought that the decrease in the amount of corticosterone in plasma was suppressed, and it is thought that it also contributes to the suppression of the decrease in plasma corticosterone concentration, and these effects were particularly remarkable in the non-low protein diet group. That is, it was found that milk protein intake, particularly sufficient milk protein intake, contributes to the suppression of adrenal insufficiency in subjects under stress.

Claims (8)

An adrenal insufficiency inhibitor containing milk protein as an active ingredient ,
wherein said milk protein is casein protein,
(i) for ingestion by a subject under heat stress, and/or
(ii) to allow humans to ingest the milk protein in a total protein amount of 0.2 g/kg body weight or more per day;
, an adrenal hypofunction inhibitor . 2. The inhibitor of adrenal insufficiency according to claim 1, which is an inhibitor of adrenal hypofunction. 2. The inhibitor of adrenal insufficiency according to claim 1, which is a cortisol or corticosterone hyposecretion inhibitor. The agent for suppressing adrenal insufficiency according to any one of claims 1 to 3, which is to be ingested by a subject under stress. The agent for suppressing adrenal insufficiency according to any one of claims 1 to 4, which is to be ingested by a subject under heat stress. 6. The inhibitor of adrenal insufficiency according to any one of claims 1 to 5 , for ingesting milk protein in humans so that the total protein amount is 0.2 g/kg body weight or more per day. The inhibitor for adrenal insufficiency according to any one of claims 1 to 5 , which is in a unit packaging form per serving and contains 5 g or more of milk protein as a total protein amount per meal in the unit packaging form. . A food for suppressing adrenal insufficiency containing milk protein as an active ingredient ,
wherein said milk protein is casein protein,
(i) for ingestion by a subject under heat stress, and/or
(ii) to allow humans to ingest the milk protein in a total protein amount of 0.2 g/kg body weight or more per day;
A food for suppressing adrenal insufficiency .

Images